|Former: Atención Farmacéutica|
|Journal edited by Rasgo Editorial since 1983|
Manuela Velázquez Prieto
EDITOR IN CHIEF
Jaime E. Poquet Jornet
Tomás Casasín Edo
Virginia Hernández Corredoira
Ramón Jódar Masanés
Juan Carlos Juárez Giménez
Volume 19 - Issue 5, September-October 2017
SUGAMMADEX 50 MG/5 ML ALLOWS CLINICIANS RATIONALIZE ITS USE FOR RESIDUAL NEUROMUSCULAR BLOCKADE REVERSAL
FAURA MESSA ANA, CASASIN EDO TOMÁS, BLANCO VARGAS DOMINGO, RIGO BONNIN RAÚL
Introduction: Sugammadex reverses very effciently residual rocuronium-induced neuromuscular block at doses range 0.5-1 mg/kg. The current cost of a 200 mg-vial sugammadex (the smallest marketed unit dose) is €71. No previous studies have been performed with lower total milligram unit doses with a proportionally reduced
The objectives of this study were to evaluate the cost of 50 mg unit dose and to demonstrate the stability of 50 mg/5 ml pre-filled syringes.
Method: Retrospective, observational study was performed in a 117-bed primary hospital. Since 2014, the Pharmacy Department provides surgical areas with sugammadex 200 mg vials and 50 mg unit doses. We compared a cohort of patients scheduled for elective surgery under general anesthesia who received sugammadex for neuromuscular reversion before (2013) and after sugammadex 50 mg/5 ml syringes implementation (2014). Clinical Laboratory studied its time stability by Ultra Performance Liquid Chromatography.
Results: No differences between the number and type of surgical procedures were found in 2013 and 2014. In 2014, sugammadex consumption decreased from 880 vials to 140 vials and 700 pre-filled syringes, which represented a cost saving of €33,866. The proportion of syringes versus vials increased progressively in 2015 and 2016.
Fifty mg/5 ml sugammadex syringes maintained its stability at least for 60 days. Conclusions: Sugammadex 50 mg/5 ml syringes are stable for at least 60 days and allows clinicians to rationalize its use, which represents a significant saving.
RESIDUAL NEUROMUSCULAR BLOCK – ROCURONIUM – SUGAMMADEX FRACTIONATION – COST ANALYSIS – ANESTHESIA